Creative Capital Management Investments LLC Acquires 637 Shares of Amgen Inc. (NASDAQ:AMGN)

Creative Capital Management Investments LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5,308.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 649 shares of the medical research company’s stock after acquiring an additional 637 shares during the period. Creative Capital Management Investments LLC’s holdings in Amgen were worth $209,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Strategic Financial Concepts LLC purchased a new stake in Amgen in the second quarter worth $26,000. Hershey Financial Advisers LLC bought a new stake in Amgen during the 2nd quarter valued at about $30,000. nVerses Capital LLC purchased a new stake in Amgen in the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen in the 2nd quarter worth about $33,000. Finally, Matrix Trust Co purchased a new position in shares of Amgen during the third quarter worth approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $319.22 on Friday. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a market cap of $171.53 billion, a PE ratio of 40.87, a P/E/G ratio of 2.84 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The business has a 50-day simple moving average of $324.47 and a two-hundred day simple moving average of $315.19.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 181.58%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period last year, the business earned $4.96 EPS. As a group, equities analysts expect that Amgen Inc. will post 19.48 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday. TD Cowen increased their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Robert W. Baird restated an “underperform” rating and set a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Morgan Stanley cut their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.